Innovative, Psychedelic Treatments In Development For Veterans

Can psychedelic medicine be a groundbreaking treatment for veterans and frontline workers?

A groundbreaking psychedelics research company is working on introducing new treatments for veterans who suffer from PTSD and other neurological conditions. NeuroPharm, under the umbrella of Mydecine, is working on a new, evidence-based medicine to help those who suffer from PTSD, as well as to treat depression anxiety, panic disorders, addiction, cluster headaches, and migraines.
 
“According to recent, published data, as many as 20 veterans on average commit suicide per day in the U.S. alone, and, to me, this is a heart-breaking staggering statistic that unfortunately is overlooked by so many. We owe everything to our veterans, EMS and frontline personnel, yet the best solutions for their long-term mental health are currently non-existent,” said Mydecine CEO Josh Bartch in a press release. “Aligning ourselves with the amazing team at NeuroPharm affords us the ability to make a positive change. Myself and the rest of the Mydecine team are truly honored to be a part of this effort to finally make a difference, and we are incredibly excited about what we will all accomplish together.”